FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * SALANS LESTER B   2. Issuer Name and Ticker or Trading Symbol Forest Laboratories, LLC [FRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE 3. Date of Earliest Transaction (Month/Day/Year) 07/01/2014 (Street) NEW YORK, NY 10022 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/01/2014   D   22,478 D (1) 0 D   Restricted Stock 07/01/2014   D   2,967 D (2) 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$ 45.32	07/01/2014		D			4,000	(3)	08/11/2014	Common Stock	4,000	(4)	0	D
Stock Option (Right to Buy)	$ 40.32	07/01/2014		D			4,000	(5)	08/08/2015	Common Stock	4,000	(4)	0	D
Stock Option (Right to Buy)	$ 46.11	07/01/2014		D			4,000	(6)	08/07/2016	Common Stock	4,000	(4)	0	D
Stock Option (Right to Buy)	$ 39.88	07/01/2014		D			4,000	(7)	08/12/2017	Common Stock	4,000	(4)	0	D
Stock Option (Right to Buy)	$ 38.33	07/01/2014		D			4,000	(8)	08/11/2018	Common Stock	4,000	(4)	0	D
Stock Option (Right to Buy)	$ 26.25	07/01/2014		D			4,000	(9)	08/10/2019	Common Stock	4,000	(4)	0	D
Stock Option (Right to Buy)	$ 28.23	07/01/2014		D			5,621	(10)	08/08/2020	Common Stock	5,621	(4)	0	D
Stock Option (Right to Buy)	$ 33.43	07/01/2014		D			5,546	(11)	08/22/2021	Common Stock	5,546	(4)	0	D
Stock Option (Right to Buy)	$ 34.54	07/01/2014		D			7,815	(12)	08/22/2022	Common Stock	7,815	(4)	0	D
Stock Option (Right to Buy)	$ 42.61	07/01/2014		D			5,909	(13)	08/14/2023	Common Stock	5,909	(4)	0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SALANS LESTER B C/O FOREST LABORATORIES, INC. 909 THIRD AVENUE NEW YORK, NY 10022	X

Signatures

/s/ Rita Weinberger as attorney-in-fact for Lester B. Salans		07/02/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each share of common stock was disposed of pursuant to the Merger Agreement, dated as of February 17, 2014 (the "Merger Agreement"), by and among the issuer and Actavis plc ("Actavis"), Tango US Holdings Inc., Tango Merger Sub 1 LLC, and Tango Merger Sub 2 LLC in exchange for either (A) $26.04 in cash plus 0.3306 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger or (B) $25.67 in cash plus 0.332623 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger, depending on the consideration election made by the reporting person and the consideration election proration procedures set forth in the Merger Agreement.
(2)	Pursuant to the terms of the Merger Agreement, each restricted share of common stock converted as of the effective time of the transaction into the right to receive $103.43 in cash.
(3)	The options are currently exercisable.
(4)	Pursuant to the terms of the Merger Agreement, (a) each vested option to purchase issuer common stock was assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such vested option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of such vested option by (y) 0.4723; and (b) each unvested option to purchase common stock converted as of the effective time of the transaction into the right to receive an amount in cash equal to the product of the excess, if any, of $103.43 over the exercise price per share of such unvested option multiplied by the number of shares of issuer common stock subject to such option.
(5)	The options are currently exercisable.
(6)	The options are currently exercisable.
(7)	The options are currently exercisable.
(8)	The options are currently exercisable.
(9)	The options are currently exercisable.
(10)	The options are currently exercisable.
(11)	The options are currently exercisable.
(12)	The options are currently exercisable.
(13)	The options are currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.